Name:

Title:

Organization:

Email:

**PMC 2021 Planning**

**Discussion Questions**

1. From your perspective are there any **new, or high-priority, policy issues** impacting personalized medicine that the coalition should consider engaging in 2021? Are there any issues that have the potential to emerge as a high priority?
*Note: You can find PMC’s* 2020 Policy Agenda[*here*](http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/PMC-2020-Policy-Agenda_FINAL2.pdf) *and an archive of PMC’s comments on an array of policy issues* [*here*](http://www.personalizedmedicinecoalition.org/Policy)*.*
2. Given the long-term impact **COVID-19** may have on the health system and patient care, as well as personalized medicine, where do you think PMC could be most effective in engaging related policy discussions to advocate for personalized medicine?
3. Which policy issues should PMC consider raising with the **Congressional Personalized Medicine Caucus** as potential 2021 priorities for personalized medicine?
4. **Diversity, equity and inclusion** are important issues impacting patients’ access to personalized medicine. How can PMC be helpful in promoting diversity, equity and inclusion in personalized medicine, both in medical research and health care delivery?
5. PMC’s **evidence development program** currently has [eight projects](http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/PMC_Understanding_and_Delivering_the_Clinical_and_Economic_Benefits_of_Personalized_Medicine.pdf) in various states of progress to generate evidence supporting the clinical and economic utility of personalized medicine in multiple disease states. Do you have suggestions for future projects that would support the evidence base for personalized medicine?
6. PMC recently released a [report](https://prn.to/32d5TzV) identifying 45 research questions to improve the delivery of personalized medicine in ways most meaningful to patients. How can PMC be helpful and support the patient and research communities inmoving forward with this **patient-centered research agenda**?
7. How can PMC help **educate** **patients** about personalized medicine and related policy issues? If you are a patient advocacy organization, how could PMC better support your efforts?
8. Are there any changes you would like to see to PMC’s **Public and Science Policy Committee Meetings** in 2021? Which topics or guest speakers would you be interested to see?
9. Finally, how can PMC improve **your engagement** in our policy activities, either in general or through our policy committees and working groups?

*Note: You can find a list of our committees and working groups* [*here*](http://www.personalizedmedicinecoalition.org/Members/Member_Benefits)*. If you would like to update the contacts from your organization participating in these forums or receiving PMC emails, please contact David Davenport at* *ddavenport@personalizedmedicinecoalition.org**.*

We appreciate your thoughtfulness in sharing feedback and your participation in our policy agenda development process. **Please send your responses, and any questions, to David Davenport, PMC Manager, Public Policy & Secretary to the Board, at** **ddavenport@personalizedmedicinecoalition.org** **by Tuesday, October 6.**